Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

  • End date
    Jan 25, 2024
  • participants needed
  • sponsor
    Alliance for Clinical Trials in Oncology
Updated on 25 October 2020
V. Suzanne Klimberg, MD, PhD
Primary Contact
Contra Costa Regional Medical Center (8.4 mi away) Contact
+50 other location
breast surgery
carcinoma in situ
breast carcinoma
invasive breast cancer
ductal carcinoma in situ
lobular carcinoma in situ
sentinel lymph node biopsy
isosulfan blue


This phase III trial studies how well axillary reverse mapping works in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast so as to prevent lymphedema after surgery.



I. To determine the occurrence of post-surgery lymphedema by conical geometric measures in clinical T1-3, N0-3, M0 breast cancer patients undergoing axillary surgery and randomized to Group 1 (no axillary reverse mapping [ARM]) versus Group II (ARM).


I. To compare between the study groups the lymphedema symptom intensity and distress as measured by the Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A).

II. To evaluate the technical success of performance of ARM procedure: Identification of ARM lymphatics, and the ability to spare or reapproximate ARM lymphatics.

III. To compare the rate of regional recurrence between patients randomized to receive ARM versus no ARM.


I. To assess the occurrence of lymphedema as a function of radiotherapy use and targets.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive isosulfan blue subcutaneously (SC) and undergo axillary lymph node dissection (ALND).

GROUP II: Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.

After completion of study, patients are followed up for 3 years.

Treatment questionnaire administration, quality-of-life assessment, Axillary Lymph Node Dissection, Isosulfan Blue, Mapping
Clinical Study IdentifierNCT03927027
SponsorAlliance for Clinical Trials in Oncology
Last Modified on25 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you female?
Do you have any of these conditions: Breast Cancer Stage III or Breast Cancer Stage I or Breast Cancer Stage II?
Documentation of Disease: cT1-3 patients undergoing axillary surgery who additionally meet one of the following conditions
Clinically node negative patients undergoing mastectomy and sentinel lymph node biopsy (SLNB) with possible axillary lymph node dissection (ALND) if SLNB is positive. If ALND is performed during a separate operation, ARM procedure must be repeated. Clinically node negative is defined by i) negative clinical exam and/or ii) negative axillary US and/or iii) negative needle biopsy of sonographically suspicious axillary nodes as applicable to each case
Clinically node positive patients as determined by needle biopsy and planned for ALND regardless of type of breast surgery
Patients will be staged according to the TNM staging system
Prior Treatment: No prior axillary surgery except needle biopsy or concurrent SLNB
Prior neoadjuvant chemotherapy is allowed but must be completed at least 2 weeks before registration
No prior history of ipsilateral breast cancer (invasive or ductal breast carcinoma in situ [DCIS]). Lobular breast carcinoma in situ (LCIS) and benign disease are allowed. (May have neoadjuvant chemotherapy which must be completed 2 weeks before registration)
No bilateral invasive breast cancer
No matted nodes
No history of lymphedema of either arm
No known allergies blue dyes, including make-up containing blue dye
In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English
Men are excluded from this study because the number of men with breast cancer
is insufficient to provide a statistical basis for assessment of effects in
this subpopulation of people with breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Creatinine: =< 1.5 x upper limit of normal (ULN)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet